Soligenix to Showcase Innovations at BIO CEO & Investor Conference in New York
Soligenix, Inc. (Nasdaq: SNGX), a pioneering late-stage biopharmaceutical company, is gearing up to present its latest developments at the renowned BIO CEO & Investor Conference, scheduled for February 10-11, 2025, in New York City. This conference is a vital platform for biopharmaceutical companies to showcase their innovations to investors, analysts, and industry professionals.
As a company dedicated to addressing rare diseases with a significant unmet medical need, Soligenix is making remarkable strides in its drug development pipeline. Among its featured products is HyBryte™ (SGX301), a revolutionary therapy that utilizes synthetic hypericin sodium for the treatment of cutaneous T-cell lymphoma (CTCL). With the successful completion of the second Phase 3 clinical trial, Soligenix aims to seek regulatory approvals for worldwide commercialization. The opportunity for one-on-one meetings with Soligenix's management allows registered attendees to engage directly about the potential of this innovative therapy and other projects in the pipeline.
In addition to HyBryte™, Soligenix is advancing several other promising candidates. These include SGX302, focused on treating psoriasis, and SGX942, aimed at treating inflammatory conditions such as oral mucositis due to head and neck cancer. The company is also working on SGX945, targeting Behçet's Disease, further demonstrating its commitment to developing unique solutions for complex health challenges.
Another significant aspect of Soligenix’s portfolio is its Public Health Solutions segment, which encompasses a range of vaccine candidates. The lead candidate, RiVax®, targets ricin toxin and is complemented by efforts to develop vaccines for filoviruses, including Marburg and Ebola, as well as CiVax™, designed to prevent COVID-19. The development of these vaccines benefits from the use of Soligenix’s proprietary heat stabilization technology, ThermoVax®, which enhances the stability of biological products. This innovative approach has been supported by substantial funding from the National Institute of Allergy and Infectious Diseases (NIAID) and other governmental agencies.
As the biopharmaceutical landscape continues to evolve, Soligenix shows resilience and adaptability by addressing urgent medical needs while navigating the complexities of drug development and commercialization. Attendees of the BIO CEO & Investor Conference will have the chance to hear directly from Soligenix's team about the company’s strategic direction and future potential in a sector that is critical for global health advancements.
For those unable to attend, Soligenix welcomes inquiries for meetings during the conference period. Interested parties can reach out to the company via their official email for scheduling arrangements. With the conference approaching, anticipation is building for what promises to be an enlightening presentation from a company committed to transforming healthcare outcomes for patients worldwide.
For more details about Soligenix and their innovative therapies, you can visit their official website at www.soligenix.com and follow them on social media through LinkedIn and Twitter at @Soligenix_Inc.
As a company dedicated to addressing rare diseases with a significant unmet medical need, Soligenix is making remarkable strides in its drug development pipeline. Among its featured products is HyBryte™ (SGX301), a revolutionary therapy that utilizes synthetic hypericin sodium for the treatment of cutaneous T-cell lymphoma (CTCL). With the successful completion of the second Phase 3 clinical trial, Soligenix aims to seek regulatory approvals for worldwide commercialization. The opportunity for one-on-one meetings with Soligenix's management allows registered attendees to engage directly about the potential of this innovative therapy and other projects in the pipeline.
In addition to HyBryte™, Soligenix is advancing several other promising candidates. These include SGX302, focused on treating psoriasis, and SGX942, aimed at treating inflammatory conditions such as oral mucositis due to head and neck cancer. The company is also working on SGX945, targeting Behçet's Disease, further demonstrating its commitment to developing unique solutions for complex health challenges.
Another significant aspect of Soligenix’s portfolio is its Public Health Solutions segment, which encompasses a range of vaccine candidates. The lead candidate, RiVax®, targets ricin toxin and is complemented by efforts to develop vaccines for filoviruses, including Marburg and Ebola, as well as CiVax™, designed to prevent COVID-19. The development of these vaccines benefits from the use of Soligenix’s proprietary heat stabilization technology, ThermoVax®, which enhances the stability of biological products. This innovative approach has been supported by substantial funding from the National Institute of Allergy and Infectious Diseases (NIAID) and other governmental agencies.
As the biopharmaceutical landscape continues to evolve, Soligenix shows resilience and adaptability by addressing urgent medical needs while navigating the complexities of drug development and commercialization. Attendees of the BIO CEO & Investor Conference will have the chance to hear directly from Soligenix's team about the company’s strategic direction and future potential in a sector that is critical for global health advancements.
For those unable to attend, Soligenix welcomes inquiries for meetings during the conference period. Interested parties can reach out to the company via their official email for scheduling arrangements. With the conference approaching, anticipation is building for what promises to be an enlightening presentation from a company committed to transforming healthcare outcomes for patients worldwide.
For more details about Soligenix and their innovative therapies, you can visit their official website at www.soligenix.com and follow them on social media through LinkedIn and Twitter at @Soligenix_Inc.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.